# Supplementary file 2: Questions to aid data extraction

Questions to guide extraction and adaptation. Adapted from EUnetHTA: HTA Core Model for Rapid Relative Effectiveness (1).

|  |  |
| --- | --- |
| **Topic**  | **Question**  |
| **Description and technical characteristics of the technology**  |
| Features of the technology   | What types of mammography are available and are there other test/comparators?  |
| Features of the technology  | What is the claimed benefit of the mammography in relation to the comparator(s)?  |
| Features of the technology  | Who administers the mammography and the comparator(s) and in what context and level of care are they provided?  |
| Investments and tools required to use the technology | What kind of special premises are needed to use mammography and the comparator(s)?  |
| Investments and tools required to use the technology | What equipment and supplies are needed to use mammography and the comparator(s)?  |
| Regulatory status  | What is the reimbursement status of the mammography?  |
| **Health problem and current use of technology**  |
| Target condition  | What are the known risk factors for breast cancer?  |
| Target condition  | What is the natural course of breast cancer?  |
| Target condition  | What are the symptoms and the burden of disease or health condition for the patient?  |
| Target condition  | What are the consequences of breast cancer for the society?  |
| Current management of the condition  | How is breast cancer currently diagnosed according to published guidelines and in practice?  |
| Current management of the condition  | How is breast cancer currently managed according to published guidelines and in practice?  |
| Target population  | What is the target population in this assessment?  |
| Target population  | How many people belong to the target population?  |
| Utilization  | How much is mammography utilized?  |
| **Safety**  |
| Patient safety  | How safe is mammography in relation to the comparator(s)?  |
| Patient safety  | Are the harms related to frequency of mammography?  |
| Patient safety  | How does the frequency or severity of harms change over time or in different settings?  |
| Patient safety  | What are the susceptible patient groups that are more likely to be harmed through the use of mammography?  |
| Patient safety  | Are mammography and comparator(s) associated with user dependent harms?  |
| Safety risk management  | What kind of data/records and/or registry is needed to monitor the use of mammography and the comparator(s)?  |
| Patient safety  | What are the consequences of false-positive, false negative and incidental findings generated by using mammography from the viewpoint of patient safety?  |
| **Clinical effectiveness**  |
| Mortality  | What is the expected beneficial effect of mammography on mortality?  |
| Morbidity  | How does mammography affect symptoms and findings (severity, frequency) of breast cancer?  |
| Morbidity  | How does mammography affect progression (or recurrence) of the disease or health condition?  |
| Function  | What is the effect of mammography on patients’ body functions?  |
| Function  | How does the use of mammography affect activities of daily living?  |
| Health related quality of life  | What is the effect of mammography on generic health-related quality of life?  |
| Health related quality of life  | What is the effect of mammography on disease-specific quality of life?  |
| Patient satisfaction  | Were patients satisfied with mammography?  |
| Test accuracy  | What is the accuracy of mammography against reference standard?  |
| Test accuracy  | What is the optimal threshold value in this context?  |
| **Costs**  |
|   | What is the price of the technology being assessed and its comparators?  |
|   | What are the total costs per patient of the intervention in relation to its comparators?  |
|   | What is the budget impact of the intervention?  |
|   | What type of uncertainty is associated with cost and budget impact estimates?  |
| **Cost-effectiveness**  |
|   | What are the expected benefits and costs associated with the technology being assessed and its comparators?  |
|   | What is the incremental cost-effectiveness ratio (ICER) of the technology being assessed in relation to its comparators? What type of uncertainty (methodological, structural and parameter) is associated with the ICER estimate?  |
|   | Is the cost-effectiveness of the intervention different between patient groups (subgroups)?  |
| **Other factors (when necessary)**  |
|   | Are there any ethical, organizational, social or legal aspects specific to the intervention that should be taken into consideration in assessment?  |
|   | Is the intervention associated with any specific patient perspectives that should be taken into consideration in assessment?  |

**Reference**

1. **EUnetHTA JAWP5**. *The HTA core model® for Rapid Relative Effectiveness Assessments (Version 4.2)*. 2015.